Showing 6581-6590 of 8179 results for "".
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effec
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers-1/2461215/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston, Texas. He
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies
- 2022 Monkeypox Outbreak: Here’s What Dermatologists Need to Knowhttps://practicaldermatology.com/news/2022-monkeypox-outbreak-heres-what-dermatologists-need-to-know/2461210/As case counts of monkeypox cases increase in Europe and other parts of the globe including the US, dermatologists may have an important role to play in terms of making differential diagnoses. George Han, MD a dermatologist at Lenox Hill Hospital in New York City, spoke to Practical
- June Risser Named General Manager of Premium Skincare Business Unit at Crown Laboratorieshttps://practicaldermatology.com/news/june-risser-named-general-manager-of-premium-skincare-business-unit-at-crown-laboratories/2461207/June Risser is Crown Laboratories, Inc.’s new General Manager of Premium Skincare. She will lead the global business unit which includes StriVectin and Vita Liberata, and she will hold a position on the Executive Leadership Team. Prior to Crown, she was General Man
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir